Related Experiment Video
Updated: Jun 28, 2025
07:36
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
Published on: September 26, 2018
10.0K
Caught in action: how MSCs modulate atherosclerotic plaque.
1Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-University, Munich, Germany.
Frontiers in Cell and Developmental Biology
|April 11, 2024
Summary
Mesenchymal stromal cells (MSCs) show promise in treating atherosclerosis by regulating inflammation at plaque sites. This review explores MSCs
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Immunology
Background:
- Atherosclerosis (AS) involves arterial plaque buildup and chronic inflammation.
- Inflammatory cells, foam cells, and cytokines drive AS progression.
- Mesenchymal stromal cells (MSCs) possess anti-inflammatory and regulatory properties.
Purpose of the Study:
- To summarize the regulatory effects of MSCs in atherosclerosis.
- To explore MSC-based therapeutic strategies for AS.
- To provide a foundation for future clinical interventions.
Main Methods:
- Literature review of studies on MSCs and atherosclerosis.
- Analysis of MSC mechanisms in modulating plaque inflammation.
- Synthesis of current research on MSC transplantation for AS.
Main Results:
- MSCs can modulate inflammatory responses within atherosclerotic plaques.
- MSC transplantation is a potential therapeutic approach for AS.
- Evidence suggests MSCs can reduce plaque progression and associated inflammation.
Conclusions:
- MSCs offer a promising therapeutic avenue for atherosclerosis.
- Further research is needed to optimize MSC-based treatments.
- Targeting inflammation with MSCs could revolutionize AS management.
